MBMathieu Bollen

Mathieu Bollen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mathieu Bollen has a total of 203 co-authors. Here are the top co-authors by number of shared publications:

  • Monique Beullens

    Laboratory of Biosignaling & Therapeutics, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium

    20 shared publications
  • Aleyde Van Eynde

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

    12 shared publications
  • Bart Lesage

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Belgium

    9 shared publications
  • Mónica Ferreira

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

    9 shared publications
  • Gerd Van der Hoeven

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

    8 shared publications
  • Shannah Boens

    Laboratory of Biosignaling & Therapeutics, KU Leuven Department of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium

    7 shared publications

Latest Publications

  • Open Access

    The adeno-associated virus Rep proteins target PP4:SMEK1 by preventing substrate-recruitment

    by Bram Vandewinkel, Sophie Torrekens, Zander Claes, Mathieu Bollen, Els Henckaerts

    Adeno-associated virus (AAV) vectors are widely used for in vivo gene therapy, but their clinical effectiveness and scalable production remain limited by gaps in our understanding of AAV biology. In particular, the host–virus interactions that regulate AAV gene expression and replication are not fully defined, yet they hold key insights for engineering improved recombinant AAV (rAAV) vectors. Here, we identify the PP4:SMEK1/2 phosphatase complex as a host restriction factor that suppresses wildtype AAV replication. Active replication and Rep expression correlates with hyperphosphorylation of KAP1 S824 and RPA2 S4/8/33 , known PP4 substrates. Rep proteins directly bind the HEAT/Arm domain of the SMEK1 regulatory subunit of PP4. We further reveal that the KAP1:SMEK1 interaction is mediated by a MAPP short linear motif (SLiM) that interacts with the substrate recruitment groove of the SMEK1 EVH1 domain. Rep68 disrupts this interaction and interferes with substrate recruitment by the PP4:SMEK1/2 complex, leading to substrate hyperphosphorylation. We also uncover a multifunctional complex containing PP4:SMEK1 and PP1:NIPP1, both implicated in KAP1 S824 dephosphorylation. Together, these findings reveal a substrate-recruitment interference mechanism by which AAV Rep proteins inhibit host phosphatase activity. This mechanistic insight provides a blueprint for enhancing rAAV vector potency and production in gene therapy applications.

  • Open Access

    POLO kinase inhibits Protein Phosphatase 1 to promote the Spindle Assembly Checkpoint and prevent aneuploidy

    by Margarida Moura, João Barbosa, Inês Pinto, Nelson Leça, Sofia Cunha-Silva, Arianna Esposito Verza, Paulo D. Pedroso, Sarah Lemaire, Joana Duro, Miguel Silva, et al.

    SUMMARY: Protein phosphatase 1 (PP1) is essential for spindle assembly checkpoint (SAC) silencing and mitotic exit, but its regulation during mitosis remains ill-defined. Here, we demonstrate in vitro and in Drosophila cells that the mitotic kinase POLO phosphorylates PP1α87B at a conserved residue (T286) within a pocket implicated in the recognition of RVxF-containing target proteins. Phosphorylation of T286 inhibits PP1α87B binding to the RVxF motif of the SAC kinase MPS1, dampening the dephosphorylation of MPS1 T-loop. Phosphorylation of T286 is dynamically regulated during mitosis. It occurs at unattached/tensionless kinetochores and decreases as chromosomes congress. Expression of phosphomimetic PP1α87B T286D prevents MPS1 inactivation in metaphase and causes a SAC-dependent delay of anaphase onset. Conversely, an unphosphorylatable PP1α87B T286A mutant impairs MPS1 activation at unattached kinetochores and weakens the SAC. In vivo , larval neuroblasts expressing PP1α87B T286 phosphomutants exhibit frequent chromosome mis-segregation and aneuploidy. Thus, our findings identify POLO-mediated phosphorylation of PP1α87B as a critical regulatory strategy that fine-tunes phosphatase activity to ensure a robust and timely SAC and prevent genome instability.


  • Open Access

    PPP1R2 stimulates protein phosphatase-1 through stabilisation of dynamic subunit interactions

    by Sarah Lemaire, Mónica Ferreira, Zander Claes, Rita Derua, Madryn Lake, Gerd Van der Hoeven, Fabienne Withof, Xinyu Cao, Elora C. Greiner, Arminja N. Kettenbach, et al.

    Protein Ser/Thr phosphatase PP1 is always associated with one or two regulatory subunits or RIPPOs. One of the earliest evolved RIPPOs is PPP1R2, also known as Inhibitor-2. Since its discovery nearly 5 decades ago, PPP1R2 has been variously described as an inhibitor, activator or (metal) chaperone of PP1, but it is still unknown how PPP1R2 affects the function of PP1 in intact cells. Here, using specific research tools, we demonstrate that PPP1R2 stabilises a subgroup of PP1 holoenzymes, exemplified by PP1:RepoMan, thereby promoting the dephosphorylation of their substrates. Mechanistically, the recruitment of PPP1R2 disrupts an inhibitory, fuzzy interaction between the C-terminal tail and catalytic domain of PP1, and generates an additional C-terminal RepoMan-interaction site. The resulting holoenzyme is further stabilized by a direct PPP1R2:RepoMan interaction, which renders it refractory to competitive disruption by RIPPOs that do not interact with PPP1R2. Our data demonstrate that PPP1R2 modulates the function of PP1 by altering the balance between holoenzymes through stabilisation of specific subunit interactions.


  • Open Access

    Spontaneous and chaperone‐assisted metal loading in the active site of protein phosphatase‐1

    by Gerd Van der Hoeven, Sarah Lemaire, Xinyu Cao, Zander Claes, Spyridoula Karamanou, Mathieu Bollen

    Protein phosphatase PP1 has two active‐site metals (Zn 2+ /Fe 2+ ) that are essential for catalysis. However, when expressed in bacteria, PP1 has two Mn 2+ ‐ions in its active site, indicating that the incorporation of Zn 2+ /Fe 2+ depends on additional eukaryotic component(s). Here, we used purified, metal‐deficient PP1 to study metal incorporation. Fe 2+ was incorporated spontaneously, but Zn 2+ was not. Mn 2+ ‐incorporation at physiological pH depended on the co‐expression of PP1 with PPP1R2 (Inhibitor‐2) or PPP1R11 (Inhibitor‐3), or a pre‐incubation of PP1 at pH 4. We also demonstrate that PPP1R2 and PPP1R11 are Zn 2+ ‐binding proteins but are, by themselves, not able to load PP1 with Zn 2+ . Our data suggest that PPP1R2 and PPP1R11 function as metal chaperones for PP1 but depend on co‐chaperone(s) and/or specific modification(s) for the transfer of associated Zn 2+ to PP1.


  • Open Access

    SDS22 coordinates the assembly of holoenzymes from nascent protein phosphatase-1

    by Xinyu Cao, Madryn Lake, Gerd Van der Hoeven, Zander Claes, Javier del Pino García, Sarah Lemaire, Elora C. Greiner, Spyridoula Karamanou, Aleyde Van Eynde, Arminja N. Kettenbach, et al.

    SDS22 forms an inactive complex with nascent protein phosphatase PP1 and Inhibitor-3. SDS22:PP1:Inhibitor-3 is a substrate for the ATPase p97/VCP, which liberates PP1 for binding to canonical regulatory subunits. The exact role of SDS22 in PP1-holoenzyme assembly remains elusive. Here, we show that SDS22 stabilizes nascent PP1. In the absence of SDS22, PP1 is gradually lost, resulting in substrate hyperphosphorylation and a proliferation arrest. Similarly, we identify a female individual with a severe neurodevelopmental disorder bearing an unstable SDS22 mutant, associated with decreased PP1 levels. We furthermore find that SDS22 directly binds to Inhibitor-3 and that this is essential for the stable assembly of SDS22:PP1: Inhibitor-3, the recruitment of p97/VCP, and the extraction of SDS22 during holoenzyme assembly. SDS22 with a disabled Inhibitor-3 binding site co-transfers with PP1 to canonical regulatory subunits, thereby forming non-functional holoenzymes. Our data show that SDS22, through simultaneous interaction with PP1 and Inhibitor-3, integrates the major steps of PP1 holoenzyme assembly.


  • Open Access

    Embryonic NIPP1 Depletion in Keratinocytes Triggers a Cell Cycle Arrest and Premature Senescence in Adult Mice

    by Marloes C.M. Jonkhout, Tijs Vanhessche, Mónica Ferreira, Iris Verbinnen, Fabienne Withof, Gerd Van der Hoeven, Kathelijne Szekér, Zahra Azhir, Wen-Hui Lien, Aleyde Van Eynde, et al.

  • Open Access

    DNA damage‐induced allosteric activation of protein phosphatase PP1:NIPP1 through Src kinase‐induced circularization of NIPP1

    by Dan Wu, Gerd Van der Hoeven, Zander Claes, Aleyde Van Eynde, Mathieu Bollen

    Protein phosphatase‐1 (PP1) complexed to nuclear inhibitor of PP1 (NIPP1) limits DNA repair through dephosphorylation of NIPP1‐recruited substrates. However, the PP1:NIPP1 holoenzyme is completely inactive under basal conditions, hinting at a DNA damage‐regulated activation mechanism. Here, we report that DNA damage caused the activation of PP1:NIPP1 after a time delay of several hours through phosphorylation of NIPP1 at the C‐terminal tyrosine 335 (Y335) by a Src‐family kinase. PP1:NIPP1 activation partially resulted from the dissociation of the C terminus of NIPP1 from the active site of PP1. In addition, the released Y335‐phosphorylated C terminus interacted with the N terminus of NIPP1 to enhance substrate recruitment by the flanking forkhead‐associated (FHA) domain. Constitutive activation of PP1:NIPP1 by knock‐in of a phospho‐mimicking (Y335E) NIPP1 mutant led to the hypo‐phosphorylation of FHA ligands and an accumulation of DNA double‐strand breaks. Our data indicate that PP1:NIPP1 activation through circularization of NIPP1 is a late response to DNA damage that contributes to the timely recovery from damage repair.


  • Top Cited Papers
    Open Access

    Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases

    by Vishnu Raman, Nele Van Dessel, Christopher L. Hall, Victoria E. Wetherby, Samantha A. Whitney, Emily L. Kolewe, Shoshana M. K. Bloom, Abhinav Sharma, Jeanne A. Hardy, Mathieu Bollen, et al.

    Critical cancer pathways often cannot be targeted because of limited efficiency crossing cell membranes. Here we report the development of a Salmonella-based intracellular delivery system to address this challenge. We engineer genetic circuits that (1) activate the regulator flhDC to drive invasion and (2) induce lysis to release proteins into tumor cells. Released protein drugs diffuse from Salmonella containing vacuoles into the cellular cytoplasm where they interact with their therapeutic targets. Control of invasion with flhDC increases delivery over 500 times. The autonomous triggering of lysis after invasion makes the platform self-limiting and prevents drug release in healthy organs. Bacterial delivery of constitutively active caspase-3 blocks the growth of hepatocellular carcinoma and lung metastases, and increases survival in mice. This success in targeted killing of cancer cells provides critical evidence that this approach will be applicable to a wide range of protein drugs for the treatment of solid tumors.